NASDAQ:APTOAptose Biosciences Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.38 +0.27 (+3.80 %) (As of 05/29/2020 04:00 PM ET) Add Compare Share Today's Range$7.06Now: $7.38▼$7.4350-Day Range$6.23MA: $7.54▼$8.4352-Week Range$1.81Now: $7.38▼$9.25Volume298,251 shsAverage Volume735,100 shsMarket Capitalization$562.87 millionP/E RatioN/ADividend YieldN/ABeta1.68 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAptose Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Aptose Biosciences has a potential upside of 62.6% from its current price of $7.38.Amount of Analyst CoverageAptose Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAptose Biosciences has received 339 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAptose Biosciences has received 280 “underperform” votes. (Add your “underperform” vote.)Community SentimentAptose Biosciences has received 54.77% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aptose Biosciences and other stocks. Vote “Outperform” if you believe APTO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APTO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAptose Biosciences does not currently pay a dividend.Dividend GrowthAptose Biosciences does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptose Biosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $19,788.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.34% of the stock of Aptose Biosciences is held by insiders.Percentage Held by Institutions46.09% of the stock of Aptose Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Aptose Biosciences are expected to decrease in the coming year, from ($0.65) to ($0.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aptose Biosciences is -13.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aptose Biosciences is -13.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAptose Biosciences has a P/B Ratio of 6.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™2.04 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APTO Previous Symbol CUSIPN/A CIK882361 Webwww.aptose.com Phone858-926-2730Debt Debt-to-Equity RatioN/A Current Ratio20.56 Quick Ratio20.56Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.14 per share Price / Book6.47Profitability EPS (Most Recent Fiscal Year)($0.52) Net Income$-26,280,000.00 Net MarginsN/A Return on Equity-53.31% Return on Assets-48.99%Miscellaneous Employees31 Outstanding Shares76,270,000Market Cap$562.87 million Next Earnings Date8/4/2020 (Estimated) OptionableOptionable NASDAQ:APTO Rates by TradingView Receive APTO News and Ratings via Email Sign-up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter. Aptose Biosciences (NASDAQ:APTO) Frequently Asked Questions How has Aptose Biosciences' stock been impacted by COVID-19 (Coronavirus)? Aptose Biosciences' stock was trading at $5.84 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, APTO shares have increased by 26.4% and is now trading at $7.38. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Aptose Biosciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aptose Biosciences. When is Aptose Biosciences' next earnings date? Aptose Biosciences is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Aptose Biosciences. How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) released its quarterly earnings results on Tuesday, May, 5th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.05. View Aptose Biosciences' earnings history. What price target have analysts set for APTO? 4 brokers have issued 1 year price targets for Aptose Biosciences' shares. Their forecasts range from $9.00 to $16.00. On average, they expect Aptose Biosciences' share price to reach $12.00 in the next year. This suggests a possible upside of 62.6% from the stock's current price. View analysts' price targets for Aptose Biosciences. Has Aptose Biosciences been receiving favorable news coverage? News stories about APTO stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Aptose Biosciences earned a daily sentiment score of -1.4 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent news coverage is unlikely to have an impact on the company's share price in the next several days. View the latest news aboutAptose Biosciences. Are investors shorting Aptose Biosciences? Aptose Biosciences saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 991,600 shares, an increase of 59.6% from the April 30th total of 621,300 shares. Based on an average daily volume of 995,400 shares, the days-to-cover ratio is presently 1.0 days. Currently, 1.4% of the shares of the company are short sold. View Aptose Biosciences' Current Options Chain. Who are some of Aptose Biosciences' key competitors? Some companies that are related to Aptose Biosciences include Bill.com (RVMD), Adverum Biotechnologies (ADVM), Sangamo Therapeutics (SGMO), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT), Regenxbio (RGNX), I-Mab (BDTX), Mesoblast (MESO), Twist Bioscience (TWST), Coherus Biosciences (CHRS), Beam Therapeutics (BEAM), Cortexyme (CRTX), Translate Bio (TBIO), NanoString Technologies (NSTG) and Proteon Therapeutics (PRTO). View all competitors. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aurinia Pharmaceuticals (AUPH), Aurora Cannabis (ACB), NVIDIA (NVDA), Arch Therapeutics (ARTH), Canopy Growth (CGC), Micron Technology (MU), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Anavex Life Sciences (AVXL) and CymaBay Therapeutics (CBAY). Who are Aptose Biosciences' key executives? Aptose Biosciences' management team includes the following people: Dr. William G. Rice Ph.D., Chairman, Pres & CEO (Age 59)Mr. Gregory K. Chow CPA, MBA, BA, Sr. VP, CFO & Principal Accounting Officer (Age 45)Mr. Ernest Kitt B.S., M.S, VP of Devel. & Technical OperationsDr. Stephen B. Howell, Chief Medical Officer (Age 73)Mr. Peter Murray, Director of Clinical Devel. What is Aptose Biosciences' stock symbol? Aptose Biosciences trades on the NASDAQ under the ticker symbol "APTO." Who are Aptose Biosciences' major shareholders? Aptose Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Corriente Advisors LLC (3.83%), Pictet Asset Management Ltd. (2.08%), Precept Management LLC (1.02%), Orbimed Advisors LLC (0.74%), P.A.W. Capital Corp (0.79%) and Morgan Stanley (0.53%). Company insiders that own Aptose Biosciences stock include Erich Platzer, Gregory K Chow and William G Rice. View institutional ownership trends for Aptose Biosciences. Which institutional investors are selling Aptose Biosciences stock? APTO stock was sold by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Sanders Morris Harris LLC, P.A.W. Capital Corp, Morgan Stanley, Morgan Stanley, and Two Sigma Advisers LP. View insider buying and selling activity for Aptose Biosciences. Which institutional investors are buying Aptose Biosciences stock? APTO stock was acquired by a variety of institutional investors in the last quarter, including Corriente Advisors LLC, Pictet Asset Management Ltd., Precept Management LLC, Atom Investors LP, BNP Paribas Arbitrage SA, Advisor Group Holdings Inc., Patriot Financial Group Insurance Agency LLC, and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Aptose Biosciences stock in the last two years include Gregory K Chow, and William G Rice. View insider buying and selling activity for Aptose Biosciences. How do I buy shares of Aptose Biosciences? Shares of APTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aptose Biosciences' stock price today? One share of APTO stock can currently be purchased for approximately $7.38. How big of a company is Aptose Biosciences? Aptose Biosciences has a market capitalization of $562.87 million. The biotechnology company earns $-26,280,000.00 in net income (profit) each year or ($0.52) on an earnings per share basis. Aptose Biosciences employs 31 workers across the globe. What is Aptose Biosciences' official website? The official website for Aptose Biosciences is www.aptose.com. How can I contact Aptose Biosciences? Aptose Biosciences' mailing address is 12770 HIGH BLUFF DRIVE SUITE 120, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-926-2730 or via email at [email protected] This page was last updated on 5/30/2020 by MarketBeat.com Staff
